Skip to main content
. Author manuscript; available in PMC: 2020 Sep 19.
Published in final edited form as: Cell Chem Biol. 2019 Jun 27;26(9):1240–1252.e11. doi: 10.1016/j.chembiol.2019.06.003

Figure 7. Foretinib synergizes with the potent AURKB inhibitor barasertib in MYC-amplified SCLC cells.

Figure 7.

(A) Dose response curves for inhibition of viability of MYC-amplified SCLC cells after 72 hours treatment with barasertib (BARA) alone or in combination with 250 nM of foretinib (FORE), n = 3, Data are represented as mean ± SD.

(B) Analysis of synergistic effects on cell viability upon combination of foretinib (FORE) and barasertib (BARA) at the indicated concentrations. Synergy was determined using the Bliss model of independence. ΔBliss indicates the difference of observed inhibition of viability to the theoretically calculated additive effect. *** indicates p value < 0.001 as determined using Student’s t-test, n = 3, Data are represented as mean ± SD.

(C) Western blot analysis for PARP1 and caspase-3 cleavage in MYC-amplified SCLC cells after 24 hours of treatment with barasertib (concentrations as in (B)), foretinib (250 nM) or their combination. Dashed lines indicate deletion of additional lanes. Blots are representative of three independent experiments.